Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 25 June 2019. Bert van Meurs.

Executive Summary

Bert van Meurs, chief business leader of Philips' image-guided therapy business, recently spoke with Medtech Insight about two new product launches to add to the Azurion angiographic platform and the new partnership with Microsoft's HoloLens 2 mixed realty technology, among other new developments. See what van Meurs said about it here.

"So, I believe that the greatest opportunity is in the digitization and the application of artificial and adaptive intelligence to have a first-time-right diagnosis but also a more effective treatment. The other opportunity that we see, and of course that's one of the main areas I'm responsible for, is in minimally invasive treatments." – Bert van Meurs, chief business leader, Philips' image-guided therapy business

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel